Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 705

Results For "AI"

7086 News Found

Zydus Cadila receives final approval from USFDA for Droxidopa capsules
News | February 20, 2021

Zydus Cadila receives final approval from USFDA for Droxidopa capsules

It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.


Lupin receives approval for Droxidopa capsules
News | February 20, 2021

Lupin receives approval for Droxidopa capsules

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness


Dr. Reddy's initiates process for emergency use authorization of Sputnik V
News | February 20, 2021

Dr. Reddy's initiates process for emergency use authorization of Sputnik V

Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.


Dr. Reddy's Laboratories launches FH Tablets in the U.S. Market
News | February 19, 2021

Dr. Reddy's Laboratories launches FH Tablets in the U.S. Market

Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.


Granules India announces approval of Potassium Chloride ER Capsules
News | February 18, 2021

Granules India announces approval of Potassium Chloride ER Capsules

Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).


Steady quarter with margin improvement for Glenmark: ICICI Securities
News | February 17, 2021

Steady quarter with margin improvement for Glenmark: ICICI Securities

India business grew 11.8% YoY vs mid-single digit industry growth.


Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr
News | February 15, 2021

Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr

The jump in profit is due to the better performance of the API business.


Steady performance; for Alkem Laboratories: ICICI Securities
News | February 13, 2021

Steady performance; for Alkem Laboratories: ICICI Securities

The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21


Jubilant Pharmova recovers: ICICI Securities
News | February 13, 2021

Jubilant Pharmova recovers: ICICI Securities

Jubilant announced the completion of demerger of pharma and LSI business into two separate companies


2021 will be a game-changer for pharma industry, says experts
News | February 13, 2021

2021 will be a game-changer for pharma industry, says experts

The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse